晚期子宫内膜癌--新一代治疗方法:妇科肿瘤学会期刊俱乐部临床评论

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY Gynecologic Oncology Reports Pub Date : 2024-07-18 DOI:10.1016/j.gore.2024.101462
Todd Tillmanns , Amal Masri , Chelsea Stewart , Dana Chase , Anthony Karnezis , Lee-may Chen , Renata Urban
{"title":"晚期子宫内膜癌--新一代治疗方法:妇科肿瘤学会期刊俱乐部临床评论","authors":"Todd Tillmanns ,&nbsp;Amal Masri ,&nbsp;Chelsea Stewart ,&nbsp;Dana Chase ,&nbsp;Anthony Karnezis ,&nbsp;Lee-may Chen ,&nbsp;Renata Urban","doi":"10.1016/j.gore.2024.101462","DOIUrl":null,"url":null,"abstract":"<div><p>In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001413/pdfft?md5=07de959263f1b1783d0624cbe85715a9&pid=1-s2.0-S2352578924001413-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Advanced endometrial cancer—The next generation of treatment: A society of gynecologic oncology journal club clinical commentary\",\"authors\":\"Todd Tillmanns ,&nbsp;Amal Masri ,&nbsp;Chelsea Stewart ,&nbsp;Dana Chase ,&nbsp;Anthony Karnezis ,&nbsp;Lee-may Chen ,&nbsp;Renata Urban\",\"doi\":\"10.1016/j.gore.2024.101462\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.</p></div>\",\"PeriodicalId\":12873,\"journal\":{\"name\":\"Gynecologic Oncology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2352578924001413/pdfft?md5=07de959263f1b1783d0624cbe85715a9&pid=1-s2.0-S2352578924001413-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologic Oncology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352578924001413\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578924001413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2024 年 2 月,妇科肿瘤学会(SGO)举办了一次期刊俱乐部会议,重点讨论晚期和转移性子宫内膜癌的新治疗方案。本临床评论旨在提供该演讲的总结报告。会议介绍了癌症基因组图谱(TCGA)工作中显示的分子特征描述的重要性。会议回顾了最新的 2023 年 FIGO 子宫内膜癌分期。随后,专家小组介绍了近期四项试验(RUBY、NRG-GY018、AtTEnd 和 DUO-E 研究)所证明的前期免疫疗法在治疗晚期或复发性子宫内膜癌中的作用。DUO-E 研究对免疫疗法与 PARP 抑制剂的联合应用进行了独特的研究。这些试验在纳入标准、主要结果和维持治疗时间等方面都有独特的差异,但都取得了类似的令人鼓舞的结果,尤其是在错配修复缺陷(dMMR)子宫内膜癌方面。在晚期和复发性子宫内膜癌领域快速创新的时代,有望加强个体化治疗方法,改善子宫内膜癌患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Advanced endometrial cancer—The next generation of treatment: A society of gynecologic oncology journal club clinical commentary

In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gynecologic Oncology Reports
Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-
CiteScore
2.00
自引率
0.00%
发文量
183
审稿时长
41 days
期刊介绍: Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.
期刊最新文献
When ovarian mature teratoma peritonitis mimics cancer: What is the best treatment? High Rates of Germline Pathogenic Variants in Somali Patients with Ovarian Cancer Sleep characteristics and recurrence in platinum-sensitive ovarian cancer survivors: A prospective cohort study Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study Rehabilitation of pelvic floor dysfunction after radiation therapy for a rare gynecological cancer: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1